Elevance Health Reports Q4 and Full Year 2024 Results, 2025 Outlook Elevance Health, Inc. (NYSE: ELV) reported strong results for the fourth quarter and full year of 2024, showcasing continued growth and operational improvements despite the challenges facing the healthcare…
Triastek’s D23 (Budesonide Ileum-Targeted Tablet) Shows Positive Clinical Results Triastek has announced that its 3D-printed drug, D23 (Budesonide Ileum-Targeted Tablet), has achieved positive results in a recent clinical trial aimed at treating IgA nephropathy (IgAN). D23 is a budesonide delayed-release…
Celltrion Gets EC Approval for Avtozma® (CT-P47), Biosimilar to RoActemra® Celltrion announced today that it has received marketing authorization from the European Commission (EC) for Avtozma® (CT-P47), a biosimilar referencing the reference biologic RoActemra® (tocilizumab). This approval allows Avtozma® to…
Hartford HealthCare Partners with K Health to Transform Primary Care Hartford HealthCare has partnered with K Health to revolutionize primary care delivery in Connecticut. The collaboration aims to redefine access to primary care using advanced clinical AI. As one of…
KalVista to Present New Sebetralstat Data at AAAAI 2025 Annual Meeting KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) has announced that six of its abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World…
Iterative Health to Showcase AI Advancements at ECCO 2025 for Ulcerative Colitis Trials Iterative Health, a healthcare technology and services company focused on advancing gastrointestinal care in partnership with physicians, will present five abstracts at the European Crohn’s & Colitis…
ReCerise Signs Research Collaboration for Innovative Hepatocellular Carcinoma Treatment ReCerise Therapeutics Inc., a company focused on developing first-in-class oncology therapeutics, has announced a new research partnership with the National Cancer Centre Singapore (NCCS). The collaboration aims to create innovative treatments…
Covalon Reports Fourth Straight Quarter of Revenue Growth and Positive Earnings Covalon Technologies Ltd. (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its financial results for the first quarter of fiscal 2025, ending December 31, 2024, alongside…
Claritev Delivers Actionable Insights for Oracle Cloud HCM Customers on Healthcare Cost Optimization Claritev Corporation (“Claritev” or the “Company”) (NYSE: MPLN), formerly known as MultiPlan, a leader in healthcare technology, data, and insights, announced that its BenInsights® platform has earned…
Sensorion Receives Positive Recommendation for Audiogene Trial of SENS-501 Sensorion, a clinical-stage biotechnology company focused on developing novel therapies to treat and prevent hearing loss, has announced a positive recommendation from the Data Monitoring Committee (DMC) for its Phase 1/2…
Waystar Prices Public Offering of Common Stock Waystar Holding Corp. (Nasdaq: WAY), a leader in healthcare payments software, announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock, offered by certain investment funds of EQT…
Neuroendocrine Tumor Center of Excellence Re-Certified The Center for Neuroendocrine Tumors at the Bad Berka Central Clinic has been officially re-certified, continuing its distinction as a leading medical facility in the field. This center has been a certified European Center…